StockNews.com Initiates Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report released on Sunday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Down 1.6 %

Shares of TTNP opened at $3.61 on Friday. Titan Pharmaceuticals has a 52-week low of $3.51 and a 52-week high of $14.80. The stock has a 50 day moving average price of $4.73 and a 200 day moving average price of $5.65.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.